Patents by Inventor Brian Christopher Bishop

Brian Christopher Bishop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM
    Publication number: 20250074900
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: July 26, 2024
    Publication date: March 6, 2025
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
    Patent number: 12077526
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: September 3, 2024
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven Howard, Benjamin David Cons, Jeffrey David St. Denis, Rhian Sara Holvey, Guillaume François Parra, Kim Louise Hirst, Isabelle Anne Lemasson, David John Nash, James Daniel Osborne, Jonas Calleja Priede, Nicholas Paul Richards, Aaron Michael Dumas, Brian Christopher Bishop, David Parry-Jones, Meenakshi Sundaram Shanmugham, Darren James Dixon, Matthew James Gaunt
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM
    Publication number: 20230278989
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: January 25, 2023
    Publication date: September 7, 2023
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
    Patent number: 11603367
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: March 14, 2023
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven Howard, Jeffrey David St. Denis, Charlotte Mary Griffiths-Jones, Steven Douglas Hiscock, Alan Richard Burns, David Cousin, Kim Louise Hirst, James Daniel Osborne, Jonas Calleja Priede, Aaron Michael Dumas, Brian Christopher Bishop, David Parry-Jones, Jeremy Peter Scott, Meenakshi Sundaram Shanmugham, Peter Richard Mullens, Darren James Dixon, Matthew James Gaunt
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM
    Publication number: 20210101887
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 8, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • ? v integrin receptor antagonists
    Patent number: 7288655
    Abstract: The present invention relates to the synthesis of intermediates for the preparation of compounds of formula (A): wherein n is 2 or 3 and various salt forms of these compounds.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: October 30, 2007
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Brian Christopher Bishop, Karel Marie Joseph Brands, Ian Frank Cottrell, Cameron John Cowden, Antony John Davies, Stephen Philip Keen, David Ross Lieberman, Gavin William Stewart
  • Process for preparing peptide intermediates
    Patent number: 7262169
    Abstract: The present invention is directed to the improved synthesis of compounds of formula (I) an intermediate compound which is useful in the synthesis of the anticancer agents known as PSA conjugates.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: August 28, 2007
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Limited
    Inventors: Michael Stewart Ashwood, Brian Christopher Bishop, Ian Frank Cottrell, Khateeta Moneek Emerson, David Hands, Guo Jie Ho, Joseph Edward Lynch, Yao Jun Shi, Robert Darrin Wilson
  • Chemical synthesis of 1,4-oxazin-2-ones
    Patent number: 6046325
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I): ##STR1## wherein R.sup.1 is a C.sub.1-6 alkyl or arylC.sub.1-4 alkyl group; and R.sup.2 is a hydrogen atom, a halogen atom, or a group selected from C.sub.1-6 alkyl, CF.sub.3 or C.sub.1-6 alkoxy substituted by C.sub.1-4 alkoxy; which comprises reacting an anhydrous or hydrated glyoxal of formula (II) with a compound of formula (III): ##STR2## in the presence of an acid.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: April 4, 2000
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Michael Stewart Ashwood, Brian Christopher Bishop, Ian Frank Cottrell